Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

Also called NCT06129526

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06129526
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06129526. Randomized; double masking; primary purpose prevention. Start 2023-12 (anticipated); primary completion 2024-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
Acronym
SEASIDE
Condition
Diabetes Type 2
Condition
Hypertriglyceridemia
Condition
Diabetes Mellitus
Intervention (Dietary supplement)
EPAVasc
Intervention (Dietary supplement)
Corn Oil
Lead sponsor
University of Ioannina (class: other)
Collaborator
LIBYTEC Pharmaceutical S.A. (class: not stated)

Record details

Record id
cardio:ct-nct06129526
Content hash
b307f1135560cad4b7d92931758c26a15a29e6737d12c6874a1f4dc247156723